H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Apellis Pharmaceuticals to $83 from $92 and keeps a Buy rating on the shares following the Q2 report. The analyst says Syfovre grows as competitive pressure intensifies.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Apellis FAERS update doesn’t change Jefferies’ view on Syfovre’s safety
- Apellis price target lowered to $86 from $100 at Baird
- 3 Best Stocks to Buy Now, 7/24/2024, According to Top Analysts
- Roche failure removes potential downside for Apellis, says Baird